第1届
Targeting Cancer Stem Cells in Oncology
-有关癌治疗之癌干细胞标的化的讨论会-
期待开发出特效药
2月19日～20日
Molecular Medicine Tri-Conference重加入此讨论会，反映出作为癌治疗药标的，在制药业界和生物技术业界中，对癌干细胞(CSC)及相关路径的关心高涨之状况。此讨论会预定由业界有关人员发表个案研究，从各种充实性肿瘤分离癌干细胞，赋予特徵（从生染色体组及蛋白质体（Proteome）面）研究的最新成果、特定CSC自我再生需要的路径、在CSC内进行药标的之特定和验证的试管试验（in vitro assay）、开发癌治疗药候选的体外（in vitro）效能模式、检证以癌的信号（Notch、Hedgehog、Wnt等）传达系作为标的专案的主题。
Who should attend: Scientists from pharma, biotech and academia working on cancer biology, stem cell biology and regenerative medicine
Topics will include, but are not limited to:
- Targeting cancer signaling pathways
- Notch
- Hedgehog
- Wnt
- Isolation and characterization of cancer stem cells
- Genomic and proteomic studies
- In vitro assays for CSC target identification and validation
- In vivo efficacy models
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
